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SUMMARY
Background
Acid suppressing agents are widely used to treat the iatrogenic ulcers
following endoscopic mucosal resection for gastric neoplasms. However,
the relative merits of proton pump inhibitor or histamine2-receptor ant-
agonist for endoscopic mucosal resection-induced ulcers are not known.
Aim
To prospectively compare omeprazole and famotidine for the healing of
endoscopic mucosal resection-induced ulcers and for bleeding control.
Methods
After endoscopic mucosal resection, patients were randomly assigned to
omeprazole (20 mg/day) or to famotidine (40 mg/day) group for a
28-day treatment period. The ulcer sizes and stages, bleeding rates and
ulcer-related symptoms were compared.
Results
A total of 100 patients were randomized equally to each group. Forty-
one patients in each group were finally compared. The two groups were
comparable in terms of baseline characteristics. Twenty-eight days after
treatment, the two groups were not different with respect to ulcer stage
(P ¼ 0.137) or ulcer reduction ratio (P ¼ 0.380). No difference was
observed with respect to ulcer-related symptoms (P ¼ 0.437) and no
bleeding episode occurred in any of the 82 patients. In subgroup that
underwent endoscopic submucosal dissection, fewer patients in the
omeprazole group showed active ulcers than those in the famotidine
group (P ¼ 0.035).
Conclusion
Our results demonstrate that omeprazole may be superior to famotidine
for iatrogenic ulcers following endoscopic mucosal resection, especially
for large ulcers.
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INTRODUCTION
Endoscopic mucosal resection (EMR) is widely per-
formed as a curative treatment modality for gastric
neoplasms such as early gastric cancer (EGC) and
adenoma in many centres. Iatrogenic gastric ulcers
invariably follow EMR and acid-suppressing agents
are administered to prevent bleeding and to induce
rapid ulcer healing. Proton pump inhibitor (PPI) is a
specific inhibitor of the enzyme H+/K+-ATPase, which
is found on the secretory surface of the parietal
cells.1 PPI is a more potent inhibitor of gastric acid
secretion than histamine2-receptor antagonists (H2RA)
like cimetidine,2 and is known to be superior to
H2RA with respect to healing gastric
3–8 and duodenal
ulcers.9, 10 Moreover, PPIs are widely used as first-
line drugs for the treatment of peptic ulcers, but it is
unclear which one is better at promoting the healing
of iatrogenic ulcers after EMR between PPI and
H2RA. Studies that have compared PPI and H2RA in
terms of efficacy of healing iatrogenic ulcers and pre-
venting bleeding after EMR have not shown any dif-
ferences,11, 12 but it is difficult to generalize those
results because of the small sample sizes. This study
was conducted to elucidate the optimal treatment
regimen for iatrogenic ulcers following EMR by com-
paring PPI and H2RA in terms of ulcer healing and
the prevention of bleeding in a prospective random-
ized controlled design.
MATERIALS AND METHODS
Patients
We enrolled patients who underwent EMR for gastric
mucosal neoplasm between October 2004 and 2005
at the Seoul National University Hospital. The exclu-
sion criteria employed were as follows; (i) age below
16 or above 76; (ii) women either pregnant or at risk
of pregnancy; (iii) lactating women; (iv) previous gas-
tro-oesophageal surgery; and (v) the use of PPI,
H2RA, aspirin, a non-steroidal anti-inflammatory drug
or glucocorticoid within 7 days of EMR. At enrol-
ment, baseline characteristics like sex, age, comorbid-
ity and the presence of epigastric pain were recorded.
Written informed consents were obtained from all
participants and the ethics committee of the Seoul
National University Hospital approved the study pro-
tocol.
EMR
Endoscopic mucosal resection was performed by using
one of the following methods; (i) by endoscopic sub-
mucosal dissection (ESD) using an insulation-tipped
electrosurgical knife; (ii) by precutting and resecting
using a snare (EMR-P); (iii) by using a transparent cap
(EMR-C); or (iv) by snare polypectomy. Before EMR,
maximal diameter and location of a lesion were recor-
ded. After EMR, ulcer dimensions were calculated by
multiplying the maximal diameter by its perpendicular
diameter. Diameters were measured with a biopsy for-
ceps (FB-24K-1; Olympus, Tokyo, Japan) placed on the
ulcer surface, based on the width between the full-
opened forceps (7 mm).11 The presence of Helicobacter
pylori (H. pylori) infection was determined by histo-
logical evaluation (modified Giemsa staining) on ant-
rum and body mucosa and by the rapid urease test
(CLOtest; Kimberley-Clark, Draper, UT, USA) using a
specimen from the lesser curvature side of the antrum.
When one of these tests was positive, then we defined
it as the presence of H. pylori infection. Haemoglobin
and haematocrit levels and coagulation profiles (pro-
thrombin time and activated partial thromboplastin
time) were also checked 1 day before EMR. After EMR,
patients were randomly assigned to either the OMP
group (omeprazole 20 mg daily for 28 days) or the
FMT group (famotidine 20 mg twice daily for 28 days).
Study subjects were unaware of the therapeutic regi-
men administered, which was performed as follows;
patients in the OMP group were administered omep-
razole (20 mg) with a famotidine placebo in the morn-
ing and placebos of omeprazole and famotidine in the
evening; whereas patients in the FMT group were
administered famotidine (20 mg) with a omeprazole
placebo in the morning and evening. Endoscopists and
interviewers were also unaware of the regimens
administered. Patients were instructed not to take any
other gastrointestinal medications during the 28 days
study period.
Evaluation after 4 weeks
Upper gastrointestinal endoscopy was performed
28 days after EMR. Ulcer stages were assessed using a
six-stage system as proposed by Sakita and Fukutomi
(Table 1),13 and ulcer dimensions were determined as
described above at EMR. This measurement was taken
when ulcers were active (A1 and A2) or in the healing
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stage (H1 and H2), but not in the scar stage because
there was no measurable mucosal break. Epigastric
pain was recorded using a four-grade system (Table 2).
Compliance with medication was evaluated by count-
ing the remaining tablets and adverse events over the
4 weeks study period were recorded. Patients with
ulcers in the active or healing stage 28 days after EMR
were administered omeprazole 20 mg/day for addi-
tional 4 weeks.
Exclusion criteria at final analyses
After counting the remaining tablets on the 29th day
after EMR, patients who had taken <75% of the pre-
scribed medications were excluded from final analyses.
Patients whose post-treatment endoscopic evaluations
were performed more than 7 days after completing
medication were also excluded from final analyses.
Statistical analysis
Patient baseline characteristics were compared using
the chi-squared test, the Student’s t-test or the Mann–
Whitney test. Ulcer reduction ratios were calculated by
dividing ulcer dimensions at 4 weeks after EMR by
initial ulcer dimensions.12, 14 Ulcer reduction ratios
were compared using the Mann–Whitney test. Ulcer
stages, symptoms during treatment and the frequencies
of adverse events were compared using the chi-
squared test. P-values of <0.05 were considered to be
statistically significant. Statistical analysis was per-
formed using SPSS for Windows (version 12.0; SPSS
Inc., Chicago, IL, USA).
Sample size was calculated based on the assumption
that the endoscopic ulcer healing rate of the OMP
group was higher than that of the FMT group by
30%.15 More than 39 patients were needed per group
using a 5% significance level and a statistical power
of 80%.16 Fifty patients were enrolled in each group
due to an expected 20% loss caused by loss during
follow-up and protocol violations.
RESULTS
A total of 100 patients were enrolled and randomly
assigned equally to the two groups. Nine patients in
each group were excluded from the final analyses
because of loss during follow-up or a failure to meet
the requirements of the final analyses. Baseline char-
acteristics, e.g. sex, age, comorbidity, epigastric pain,
blood test and H. pylori positivity (Table 3) and char-
acteristics, such as lesion size and location, EMR
method used and haemostasis after EMR and histopa-
thology (Table 4) were not significantly different
between the two groups.
The stages of the 82 ulcers on follow-up endoscopy
were compared between the two groups (Figure 1) and
no significant difference was found in terms of ulcer
stage distribution (P ¼ 0.137). Twenty-three patients
Table 1. Gastric ulcer stages
using a six-stage system
Stage Finding
A1 (active stage 1) Ulcer that contains mucus coating, with marginal elevation
because of oedema
A2 (active stage 2) Mucus-coated ulcer with discrete margin and less oedema than
active stage 1
H1 (healing stage 1) Unhealed ulcer covered by regenerating epithelium <50 %, with
or without converging folds
H2 (healing stage 2) Ulcer with a mucosal break but almost covered with regenerating
epithelium
S1 (scar stage 1) Red scar with rough epithelialization without mucosal break
S2 (scar stage 2) White scar with complete re-epithelialization
English version of ulcer stages as classified by Sakita and Fukutomi.13
Table 2. Grading system of epigastric pain
Grade Severity
None Without epigastric pain
Mild Minimal epigastric pain
Moderate With epigastric pain, without disturbing
activities of daily living
Severe With epigastric pain with disturbing
activities of daily living
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among 41 patients (56.1%) in each groups were
remained in stage A2 or H1 in both groups; however,
a much smaller proportion (one among 41 patients;
2.4%) of patients in the OMP group showed stage A2
than that (seven among 41 patients; 17.1%) of patients
in the FMT group. When stages of ulcers were classi-
fied using a three-stage system, i.e. active, healing or
scar stage, the distribution of ulcer stages differed with
marginal significance between the two study groups
(P ¼ 0.057).
Table 3. Characteristics of patients in both groups
Variables
Omeprazole group
(n ¼ 41)
Famotidine group
(n ¼ 41) P-value
Male 28 (68.3%) 24 (58.5%) 0.359
Age (mean  s.d.) 61.2  9.0 58.5  9.4 0.186
Comorbidity 22 (53.7%) 15 (36.6%) 0.120
Epigastric pain
None 31 (75.6%) 29 (70.7%) 0.534
Mild 9 (22.0%) 8 (19.5%)
Moderate 1 (2.4%) 4 (9.8%)
Haemoglobin (g/dL) (mean  s.d.) 13.8  1.5 13.8  1.4 0.951
Haematocrit (%) (mean  s.d.) 40.6  4.2 40.7  4.0 0.910
Prothrombin time (INR) (mean  s.d.) 1.02  0.09 1.02  0.06 0.629
Activated partial thromboplastin time (s) (mean  s.d.) 35.9  4.6 35.3  6.3 0.607
Helicobacter pylori positivity 25 (61.0%) 23 (56.1%) 0.654
INR, International normalized ratio.
Table 4. Characteristics of
gastric lesions in the two
groupsVariables
Omeprazole
group
(n ¼ 41)
Famotidine
group
(n ¼ 41) P-value
Maximal diameter (cm) (mean  s.d.) 1.14  0.53 1.11  0.46 0.740
Location
Upper third 1 (2.4%) 1 (2.5%) 0.903
Mid third 13 (31.7%) 11 (26.8%)
Lower third 27 (65.9%) 29 (70.7%)
Method of EMR
Snare polypectomy 5 (12.2%) 8 (19.5%) 0.712
EMR-C 3 (7.3%) 3 (7.3%)
EMR-P 7 (17.1%) 9 (22.0%)
ESD 26 (63.4%) 21 (51.2%)
Haemostasis after EMR 31 (75.6%) 25 (61.0%) 0.154
Histopathology
Adenoma, low grade 16 (39.0%) 24 (58.5%) 0.071
Adenoma, high grade 5 (12.2%) 8 (19.5%)
Adenocarcinoma, W/D 10 (24.4%) 3 (7.3%)
Adenocarcinoma, M/D 5 (12.2%) 1 (2.5%)
Others 5 (12.2%) 5 (12.2%)
EMR-C, endoscopic mucosal resection using a transparent cap; EMR-P, endoscopic
mucosal resection by precutting and resecting using a snare; ESD, endoscopic submuco-
sal dissection; W/D, well differentiated; M/D, moderately differentiated.
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The ulcer reduction ratios of the 67 ulcers that were
remained in the active or healing stage on follow-up
endoscopy (34 ulcers in the OMP group and 33 ulcers
in the FMT group) were also compared. Figure 2 shows
the initial and follow-up mean dimensions of ulcers in
the two groups. In the OMP group, the initial mean
ulcer dimension 1042.9  873.1 mm2 reduced to
35.9  30.6 mm2 after 28 days (mean ulcer reduction
ratio ¼ 0.072  0.159) and in the FMT group, it
reduced from 912.6  744.0 mm2 to 40.3  42.2 mm2
after 28 days (mean ulcer reduction ratio ¼ 0.058 
0.062) and ulcer reduction ratios were not significantly
different (P ¼ 0.380). Moreover, the distribution of the
severity of epigastric pain during the study period was
not different in the two groups (P ¼ 0.437, Table 5).
Bleeding episodes or adverse events were not observed
in any of 82 study subjects.
We performed subgroup analysis for patients who
underwent ESD (26 patients in the OMP group and 21
patients in the FMT group). Baseline characteristics
were comparable between the two groups (data not
shown). In comparing ulcer stages using a six-stage
system, the distribution was not significantly different
(P ¼ 0.097). When stages of ulcers were classified
using a three-stage system as stated above, the distri-
bution of ulcer stages was significantly different (P ¼
0.035, Figure 3), i.e. a smaller proportion of patients in
the OMP group (3.8%) remained in the active stage
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Figure 1. The distribution of ulcer stages on follow-up
endoscopic examination. The numbers in graph indicate
the number of patients in each stage. No significant dif-
ference was found between the omeprazole (OMP) and
famotidine (FMT) groups (P ¼ 0.137).
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Figure 2. Mean initial and final (on follow-up endoscopy)
ulcer dimensions of the both groups. Ulcer reduction
ratios (RRs) were not significantly different (P ¼ 0.380).
Table 5. Severity of epigastric pain during the 28 days
treatment period
Severity of
epigastric
pain
Omeprazole
group
(n ¼ 41)%
Famotidine
group
(n ¼ 41)% P-value
None 26 (63.4) 22 (53.7) 0.437
Mild 11 (26.8) 12 (29.3)
Moderate 4 (9.8) 4 (9.7)
Severe 0 (0) 3 (7.3)
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Figure 3. The distribution of ulcer stages on follow-up
endoscopic examination of patients who underwent endo-
scopic submucosal dissection. The numbers in graph indi-
cate the number of patients in each stage. This shows
significant difference in the distribution of ulcer stages
(P ¼ 0.035).
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than that of the FMT group (28.6%). We also com-
pared the ulcer reduction ratios of 25 ulcers following
ESD in the OMP group and 20 ulcers following ESD in
the FMT group. The mean ulcer reduction ratios were
not significantly different (0.034  0.028 in the OMP
group vs. 0.057  0.076 in the FMT group, P ¼
0.293). The distribution of severity of ulcer-related
symptoms was also comparable (P ¼ 0.290, data not
shown).
DISCUSSION
This study was conducted to compare the efficacies of
PPI and H2RA in terms of inducing ulcer healing and
preventing bleeding after EMR for a gastric mucosal
neoplasm. Many reports have compared PPI with H2RA
in terms of healing peptic ulcers and some have repor-
ted that PPI is superior to H2RA in this respect.
3–10
Similarly, for bleeding peptic ulcers, omeprazole was
found to be more effective than H2RA in terms of redu-
cing rebleeding episodes in patients who underwent
initial endoscopic haemostasis,17 or who did not
undergo endoscopic haemostasis.18–21 EMR is widely
applied for curative treatment of gastric mucosal neo-
plasms like EGC or adenoma. Recently, the ESD tech-
nique has been adopted by many centres in Korea for
en-bloc resection of a lesion. However, after ESD, a lar-
ger artificial ulceration is created than those produced
by snare polypectomy or EMR-P. Because ulcer dimen-
sions are larger and the resection depths are greater
than those associated with the conventional method
like snare polypectomy or EMR-P, the risk of bleeding
is believed to be higher. Thus, rapid ulcer healing
through clot stabilization at an elevated intragastric pH
is required.
Generally, PPI or H2RA is used for inducing the
rapid healing of artificial gastric ulcers after EMR.
Because PPI is known to be more potent at elevating
the intragastric pH than H2RA, it can be assumed that
PPI induces ulcer healing more rapidly and prevents
bleeding episodes more efficiently than H2RA after
EMR. However, in one study which compared omep-
razole and famotidine, ulcer healing rates (assessed
using ulcer sizes) were not different.11 But the sample
size (eight patients in each treatment group) was small
and ulcer reduction ratios based on initial ulcer sizes
were not calculated. Recently, in one randomized pros-
pective study, no difference was found between famot-
idine and omeprazole in terms of bleeding rates and
ulcer reduction ratios after EMR.12
The present study involved a larger number of
patients than previous studies,11, 12 and also compared
the effectivenesses of the two drugs in terms of the
healing of larger ulcers than previous study.12 We
found no overall differences between the OMP and
FMT groups in terms of ulcer stage or ulcer reduction
ratio, although fewer patients in the OMP group
showed active stage ulcers than those in the FMT
group. However, in comparing subgroup that under-
went ESD, active stage ulcers were significantly fewer
in the OMP group than in the FMT group, although
ulcer reduction ratios were not different. No compar-
ison of ulcer stages between omeprazole and famoti-
dine treatment groups was performed in the previous
study.12
Our results suggest that omeprazole is superior to
famotidine in terms of converting active stage ulcers
into the healing stage, especially in case with a large
artificial ulcer after ESD. Recently, as the ESD tech-
nique is applied more and more widely for the treat-
ment of gastric mucosal neoplasm, the size of artificial
ulcer is increasing. Our observation indicates that
omeprazole is preferred for a large artificial ulcer than
famotidine. Increasing the dosage of omeprazole, i.e.
doubling the dose, may also be expected to accelerate
ulcer healing, thereby revealing the superiority of
omeprazole more clearly.
Minor bleedings, which stopped spontaneously or
after endoscopic haemostasis without a need for trans-
fusion or surgery, occurred in two of the 50 patients in
the OMP group (4%) and in one of the 50 patients in
the FMT group (2%). However, these three patients
were excluded from the final analyses because of pro-
tocol violations. In both groups, bleeding rates were
lower than previous study,12 which may be due to
more thorough application of an advanced haemostatic
technique. Actually, a haemostatic procedure using
haemostatic forceps and/or argon plasma coagulation
was conducted in 45 (95.7%) of 47 patients treated by
ESD. When H. pylori is detected in gastric mucosa of a
patient with peptic ulcer disease, H. pylori eradication
is a standard treatment. However, it is still uncertain
whether H. pylori eradication therapy influences the
healing of iatrogenic ulcers following EMR. Recently,
H. pylori eradication was reported not to accelerate the
iatrogenic ulcer healing although it might improve the
quality of iatrogenic ulcer healing.22 We did not eradi-
cate H. pylori routinely during the study period but
after the completion of study medications, seven
patients of the OMP group and three patients of the
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FMT group received first-line H. pylori eradication
treatment composed of PPI with amoxicillin and
clarithromycin for 7 days. Further studies are needed
to elucidate the role of H. pylori eradication in healing
of iatrogenic ulcers.
Initially, we enrolled 50 patients in each group, but
nine among 50 patients (18%) were dropped out from
each group. However, considering equal drop out rates
and comparable incidences of adverse events, our
results could be applied to the patient group having
iatrogenic ulcers after EMR.
In summary, omeprazole appeared to be more
effective in promoting healing of artificially induced
ulcers after EMR, especially in the subgroup with ESD.
A randomized controlled trial focusing on this sub-
group of patients with larger artificial ulcerations will
provide definitive data to confirm or refute the hypo-
thesis that PPI is indeed superior to H2RA after EMR.
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